CLAIMS

1. A peptide of length equal to or lower than 5 amino acids, or a derivative thereof, comprising the sequence DKY, preferably XDKY (SEQ ID No. 7) or DKYX (SEQ ID No. 8), or the sequence DRY, preferably XDRY (SEQ ID No. 9) or DRYX (SEQ ID No. 10), wherein X is any amino acid, for use as a drug.

2. The peptide according to claim 1, for use in treating a disorder resulting from pathological angiogenesis.

3. The peptide for use according to claim 2, wherein said disorder resulting from pathological angiogenesis is selected from the group consisting of tumors, chronic inflammation, and neo-vascularisation disorders.

4. The peptide for use according to any one of claims 1 to 3, wherein said peptide has a length equal to 3 or 4 amino acids.

5. The peptide for use according to any one of claims 1 to 3, wherein said derivative is a peptide wherein the N- and/or C-terminal is chemically modified or protected with an organic compound selected from the group consisting of phosphoryl (PO_3^{2-}), glycosyl, acyl, alkyl, carboxyl, amine, biotin, ubiquitin.

6. A pharmaceutical composition comprising (a) a peptide of length equal to or lower than 5 amino acids, or a derivative thereof, comprising the sequence DKY, preferably XDKY (SEQ ID No. 7) or DKYX (SEQ ID No. 8), or the sequence DRY, preferably XDRY (SEQ ID No. 9) or DRYX (SEQ ID No. 10), where X is any amino acid, and (b) at least one pharmaceutically acceptable excipient, for use as a drug.

7. The pharmaceutical composition for use according to claim 6, wherein said pharmaceutical composition comprises an amount of said peptide, or a derivative thereof, from 0.0001% to 20% by weight, preferably from 0.0001% to 15% by weight.

8. The pharmaceutical composition for use according to claim 6, wherein said composition is formulated for oral, parenteral, inhalation (spray, powder or aerosol), topical, rectal, nasal, buccal, vaginal administration or through an implanted device.

9. A pharmaceutical composition comprising (a) a peptide of length equal to or lower than 5 amino acids, or a derivative thereof, comprising the sequence DKY, preferably XDKY (SEQ ID No. 7) or DKYX (SEQ ID No. 8), or the sequence DRY, preferably XDRY (SEQ ID No. 9) or DRYX (SEQ ID No. 10), where X is any amino acid, (b) at least one pharmaceutically acceptable excipient, and (c) an antineoplastic agent.

10. The pharmaceutical composition according to claim 9, wherein said antineoplastic agent is chosen from the group consisting of (i) alkaloids, (ii) alkylating agents, (iii) antibiotics and analogs, (iv) antimetabolites, (v) immunomodulators, (vi) platinum complexes, and (vii) antineoplastic hormones or analogs.